Ziihera

Product

Last mentioned: Mar 18, 2026

Timeline

Mar 18, 2026
AACR Presentation Announcement

Zymeworks confirms multiple data sessions for Ziihera at the upcoming annual meeting.
Q4 2024
Regulatory Progress

Advancement of Biologics License Application (BLA) filings for lead indications.
June 2023
ASCO Data Release

Positive pivotal Phase 2 results in biliary tract cancer (BTC) showcased at ASCO.

Stories mentioning Ziihera 1

Zymeworks to Present New Ziihera® Data at 2026 AACR Annual Meeting

Zymeworks Inc. has announced a series of clinical and preclinical presentations for its lead asset, Ziihera® (zanidatamab-hrii), at the 2026 AACR Annual Meeting. The data will highlight the therapeutic potential of this HER2-targeted bispecific antibody across multiple oncology indications.

Mar 18, 2026 2 sources